KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)

KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).

bayer_logo.gifThe Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.

Continue Reading

U.S. Dept of Commerce asked to review Africa Intellectual Property Forum compliance w/ Executive Order 13155

Health GAP, KEI, Oxfam, Public Citizen, Universities Allied for Essential Medicines and Professor Susan Sell have written Cameron Forbes Kerry, the General Counsel for the U.S. Department of Commerce, asking Kerry to “review work on the Africa Intellectual Property Forum, currently scheduled for April 3-5, 2012 in Cape Town, South Africa, to see if the sponsorship of the event violates Executive Order 13155, on Access to HIV/AIDS Pharmaceuticals and Medical Technologies.” Executive Order 13155 was issued by President Clinton on May 10, 2000 after an extensive review of U.S. Continue Reading

Uncategorized

Seven public health groups write to oppose the “Research Works Act”

On February 8, 2012, seven public health organisations submitted a letter to Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform and the other thirty-nine members of this committee opposing H.R. 3699, the “Research Works Act.” This bill, originally introduced on December 16, 2011 by Rep. Issa and Rep. Maloney (D-NY) would prohibit federal agencies from conditioning its federal grants on recipients making its published research results available to the public. Continue Reading

Uncategorized

US, France, Japan, South Africa, WIPO, ICC-BASCAP, Lilly, Microsoft and Pfizer co-sponsor Africa IP Forum in Cape Town

The United States Department of Commerce’s Commercial Law Development Program (CLDP) is the lead agency of a concerted effort involving the governments of France, Japan, South Africa and the United States, alongside the World Intellectual Property Organization (WIPO), Organisation Africaine de la Propriété Intellectuelle (OAPI), and the African Regional Intellectual Property Organization (ARIPO) to organize the inaugural “Africa Intellectual Property Forum: Intellectual Property, Regional Integration and Economic Gr Continue Reading

Uncategorized

2012: KEI asks Senator Leahy (D-VT) to demand greater transparency in the TPPA

On January 26, 2012, KEI sent a letter to Senator Patrick Leahy (D-VT), Chairman of the Judiciary Committee, calling for greater transparency in the Trans-Pacific Partnership Agreement (TPPA). The letter highlights the fact that the general public is kept in the dark regarding negotiating positions and the actual text while “cleared advisers” and corporate lobbyists have unequal access to information. It calls for Senator Leahy to urge the Obama Administration to release the negotiating text in order to allow full and effective public participation in our democratic society.

Continue Reading

Uncategorized

EB130: CMC Churches’ Action for Health intervention on the Consultative Expert Working Group on Research and Development (CEWG)

This was the statement delivered by CMC Churches’ Action for Health intervention on 21 January 2012 on the Consultative Expert Working Group on Research and Development: Financing and Coordination at the 130th WHO Executive Board meeting.

CMC Churches’ Action for Health intervention on the Consultative Expert Working Group on Research
and Development: Financing and Coordination at the 130th WHO Executive Board meeting

WHO 130th Executive Board Agenda Item 6.14

Intervention by James Love, CMC Churches’ Action for Health

Continue Reading

Uncategorized

KEI files amicus brief in BRCA gene patent case

Since May 2009, the ACLU and Public Patent Foundation (PUBPAT) have been litigating a case involving the patent eligibility of two human genes, BRCA1 and BRCA2, associated with ovarian and breast cancer. ACLU and PUBPAT, representing the petitioners, Association for Molecular Pathology, among others, have argued that human genes are not patentable and that patents on such objects stifle diagnostic testing and further research.

Continue Reading

Uncategorized